Completed PHASE3 INTERVENTIONAL NCT00005918

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as Part of Potent Antiretroviral Combination Therapy

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections

Interventions Efavirenz Lamivudine Stavudine

Updated 8 times since 2017 Last updated: Apr 28, 2011 Started: Jun 30, 2000 Primary completion: Apr 30, 2002 Completion: Apr 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00005918, this PHASE3 trial focuses on HIV Infections and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 8 times since 2000, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Almada, Portugal , Altamonte Springs, United States , Antella, Italy , Bangkok, Thailand , Barcelona, Spain , Bari, Italy , Belo Horizonte-MG, Brazil , Bergamo, Italy , Bordeaux, France , Botucatu-SP, Brazil and 53 more locations